Unique DUOX2+ACE2+ small cholangiocytes are pathogenic targets for primary biliary cholangitis

独特的DUOX2+ACE2+小胆管细胞是原发性胆汁性胆管炎的致病靶点。

阅读:3
作者:Xi Li #,Yan Li #,Jintao Xiao #,Huiwen Wang #,Yan Guo #,Xiuru Mao #,Pan Shi #,Yanliang Hou,Xiaoxun Zhang,Nan Zhao,Minghua Zheng,Yonghong He,Jingjing Ding,Ya Tan,Min Liao,Ling Li,Ying Peng,Xuan Li,Qiong Pan,Qiaoling Xie,Qiao Li,Jianwei Li,Ying Li,Zhe Chen,Yongxiu Huang,David N Assis,Shi-Ying Cai,James L Boyer,Xuequan Huang,Can-E Tang,Xiaowei Liu,Shifang Peng,Jin Chai

Abstract

Cholangiocytes play a crucial role in bile formation. Cholangiocyte injury causes cholestasis, including primary biliary cholangitis (PBC). However, the etiology of PBC remains unclear despite being characterized as an autoimmune disease. Using single-cell RNA sequencing (scRNA-seq), fluorescence-activated-cell-sorting, multiplex immunofluorescence (IF) and RNAscope analyses, we identified unique DUOX2+ACE2+ small cholangiocytes in human and mouse livers. Their selective decrease in PBC patients was associated with the severity of disease. Moreover, proteomics, scRNA-seq, and qPCR analyses indicated that polymeric immunoglobulin receptor (pIgR) was highly expressed in DUOX2+ACE2+ cholangiocytes. Serum anti-pIgR autoantibody levels were significantly increased in PBC patients, regardless of positive and negative AMA-M2. Spatial transcriptomics and multiplex IF revealed that CD27+ memory B and plasma cells accumulated in the hepatic portal tracts of PBC patients. Collectively, DUOX2+ACE2+ small cholangiocytes are pathogenic targets in PBC, and preservation of DUOX2+ACE2+ cholangiocytes and targeting anti-pIgR autoantibodies may be valuable strategies for therapeutic interventions in PBC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。